KRAS and neoplasm: However, approximately 40% of rectal cancer patients possess KRAS mutations,5, 6, 7 which activate the RAS membrane receptor tyrosine protein kinase signaling pathway, disrupt upstream signal regulation, and promote tumor cell proliferation.